- Home
- RGS vs BLRX Comparison
RGS vs BLRX Comparison
Compare RGS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGS
- BLRX
- Stock Information
- Founded
- RGS 1922
- BLRX 2003
- Country
- RGS United States
- BLRX Israel
- Employees
- RGS N/A
- BLRX N/A
- Industry
- RGS Other Consumer Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- RGS Consumer Discretionary
- BLRX Health Care
- Exchange
- RGS Nasdaq
- BLRX Nasdaq
- Market Cap
- RGS 70.8M
- BLRX 17.1M
- IPO Year
- RGS 1991
- BLRX 2011
- Fundamental
- Price
- RGS N/A
- BLRX $4.02
- Analyst Decision
- RGS
- BLRX Strong Buy
- Analyst Count
- RGS 0
- BLRX 2
- Target Price
- RGS N/A
- BLRX $19.00
- AVG Volume (30 Days)
- RGS 17.4K
- BLRX 51.4K
- Earning Date
- RGS 11-05-2025
- BLRX 11-24-2025
- Dividend Yield
- RGS N/A
- BLRX N/A
- EPS Growth
- RGS 20.23
- BLRX N/A
- EPS
- RGS 46.10
- BLRX N/A
- Revenue
- RGS $210,134,000.00
- BLRX $17,251,000.00
- Revenue This Year
- RGS N/A
- BLRX N/A
- Revenue Next Year
- RGS N/A
- BLRX N/A
- P/E Ratio
- RGS $0.71
- BLRX N/A
- Revenue Growth
- RGS 3.52
- BLRX 1.19
- 52 Week Low
- RGS $15.00
- BLRX $2.30
- 52 Week High
- RGS $30.93
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- RGS 66.61
- BLRX 49.91
- Support Level
- RGS $28.74
- BLRX $3.70
- Resistance Level
- RGS $30.89
- BLRX $4.56
- Average True Range (ATR)
- RGS 1.09
- BLRX 0.33
- MACD
- RGS -0.11
- BLRX 0.00
- Stochastic Oscillator
- RGS 90.07
- BLRX 38.30
About RGS Regis Corporation
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.